1 A Distinct Nasal Microbiota Signature in Peritoneal Dialysis Patients
2 Iman Khan<sup>1</sup>, Sylvia Wu<sup>1</sup>, Anika Hudson<sup>1</sup>, Clayton Hughes<sup>1</sup>, Gabriel Stryjniak<sup>1</sup>, Lars F.

- Westblade<sup>2,3</sup>, Michael J. Satlin<sup>2,3</sup>, Nicholas Tedrow<sup>1</sup>, Anne-Catrin Uhlemann<sup>4</sup>, Colleen Kraft<sup>5</sup>,
- 4 Darshana M. Dadhania<sup>1,6</sup>, Jeffrey Silberzweig<sup>1,7</sup>, Iwijn De Vlaminck<sup>8</sup>, Carol Li<sup>1</sup>, Vesh
- 5 Srivatana<sup>1,7\*</sup>, John Richard Lee<sup>1,6\*</sup>
- 6 1. Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell
- 7 Medicine, New York, NY, USA
- 8 2. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York,
- 9 NY, USA
- 10 3. Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New
- 11 York, NY, USA
- 12 4. Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians
- and Surgeons Columbia University, New York, NY
- 14 5. Division of Infectious Diseases, Department of Medicine, Emory University School of
- 15 Medicine, New York, NY
- 16 6. Department of Transplantation Medicine, New York Presbyterian Hospital–Weill Cornell
- 17 Medical Center, New York, NY, USA
- 18 7. The Rogosin Institute, New York, NY, USA
- 19 8. Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA
- 20 Abstract word count: 299
- 21 Manuscript body word count: 2938
- \* V.S. and J.R.L. contributed equally to this work
- Correspondence to Dr. Vesh Srivatana, ves2009@nyp.org, or Dr. John R. Lee,
- 24 <u>jrl2002@med.cornell.edu</u>

25

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Authors' Contributions. IK, ACH, VS, and JRL designed the study. IK, VS, and JRL collected samples and clinical metadata. AH, CH, and CL processed specimens and performed experiments. IK, SW, GS, LFW, MJS, NT, ACH, CK, DMD, JS, VS, IDV, and JRL collected and analyzed data. IK, SW, GS, LFW, MJS, ACH, CK, DMD, JS, IDV, VS, and JRL wrote the manuscript. All authors read and approved the final manuscript. Funding. This study was supported in part by R21AI164093 (JRL, IDW). Financial Disclosure. DMD, JRL, and IDV hold patent US-2020-0048713-A1 titled "Methods of Detecting Cell-Free DNA in Biological Samples" licensed to Eurofins Viracor. LFW has received or receives research support from Accelerate Diagnostics, Inc., bioMérieux, Inc., Hardy Diagnostics, and Roche Molecular Systems, Inc., and consulting fees from Roche Molecular Systems, Inc., Shionogi, Inc., and Talis Biomedical. MJS reports research support from Merck, Biomérieux, and SNIPRBiome, compensation for consulting from Shionogi, and compensation for participation in a Data and Safety Monitoring Board from AbbVie. CK is a consultant for Rebiotix/Ferring and on the Scientific Advisory Board of Seres Therapeutics. DMD serves as a consultant for CareDx and is a site clinical investigator for studies sponsored by AlloVir and CSL Behring. JS is the Co-Chair of the American Society of Nephrology Workgroup on COVID-19 and other Emerging Threats and of the American Society of Nephrology Emergency Partnership Initiative and has received consulting fees from Alkahest, Bayer, Honeywell, Kaneka and St. Gobain. IDV is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. VS reports receiving speakers' fees from Baxter Healthcare. JRL

- 48 received research support under an investigator-initiated research grant from BioFire
- 49 Diagnostics, LLC. JRL receives speakers' fees from Astellas.
- 51 **Acknowledgments.** We thank Dr. Manikkam Suthanthiran for his overall guidance in this
- 52 project.

53 54

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

**ABSTRACT** Rationale & Objective. The nasal passages harbor both commensal and pathogenic bacteria. In this study, we sought to characterize the anterior nasal microbiota in PD patients using 16S rRNA gene sequencing. Study Design. Cross-sectional. Setting & Participants. We recruited 32 PD patients, 37 kidney transplant (KTx) recipients, 22 living donor/healthy control (HC) participants and collected anterior nasal swabs at a single point in time. **Predictors.** We performed 16S rRNA gene sequencing of the V4-V5 hypervariable region to determine the nasal microbiota. Outcomes. Nasal microbiota profiles were determined at the genus level as well as the amplicon sequencing variant level. **Analytical Approach.** We compared nasal abundance of common genera among the 3 groups using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment. DESeq2 was also utilized to compare the groups at the ASV levels. **Results.** In the entire cohort, the most abundant genera in the nasal microbiota included: Staphylococcus, Corvnebacterium, Streptococcus, and Anaerococcus. Correlational analyses revealed a significant inverse relationship between the nasal abundance of Staphylococcus and that of Corynebacterium. PD patients have a higher nasal abundance of Streptococcus than KTx recipients and HC participants. PD patients have a more diverse representation of Staphylococcus and Streptococcus than KTx recipients and HC participants. PD patients who concurrently have or who developed future Staphylococcus peritonitis had a numerically higher

peritonitis.

Limitations. 16S RNA gene sequencing provides taxonomic information to the genus level.

Conclusions. We find a distinct nasal microbiota signature in PD patients compared to KTx recipients and HC participants. Given the potential relationship between the nasal pathogenic bacteria and infectious complications, further studies are needed to define the nasal microbiota associated with these infectious complications and to conduct studies on the manipulation of the nasal microbiota to prevent such complications.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

INTRODUCTION The anterior nasal microbiota is at the interface between the external environment and the nasal passages and contains a combination of commensal and pathogenic bacteria. The most common genera defined in healthy individuals in the Human Microbiome Project are Staphylococcus, Corynebacterium, Propionibacterium, and Moraxella (1). Subsequent studies on the nasal microbiota have revealed microbiota dysbiosis in diseased states such as chronic rhinosinusitis (2) and have linked the nasal microbiota to infectious complications after elective surgical procedures (3). Peritoneal dialysis (PD) patients undergo dialysis through PD catheter through their abdomen. Despite being taught sterile technique, PD patients experience both exit site infections around the catheter and infectious peritonitis. Prior work has established that pathogenic bacteria in the nasal passages may be associated with infectious complications in PD patients. Luzar et al. reported that Staphylococcus aureus nasal colonization was associated with exit site infections in a cohort of 140 PD patients (4). Other studies have found that persistent nasal colonization with S. aureus was also associated with peritonitis (5, 6). Decolonization with mupirocin has been suggested to prevent infections and the MUPIROCIN Study Group found that nasal mupirocin prevented S. aureus exit site infection (7). Despite these data, International Society of Peritoneal Dialysis (ISPD) guidelines do not support the routine use of nasal mupirocin (8). Because no study to date has comprehensively evaluated the anterior nasal microbiota in PD patients, we performed a pilot study to evaluate the anterior nasal microbiota using 16S rRNA

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

gene sequencing of the V4-V5 hypervariable region in PD patients, in kidney transplant recipients, and healthy controls. **METHODS** Study Cohort Recruitment and Nasal Swab Specimen Collection From August 2021 to January 2022, we recruited patients receiving peritoneal dialysis (PD), kidney transplant (KTx) recipients, and living donor/healthy control (HC) participants for anterior nasal swab specimen collection. All kidney transplant recipients and living donor candidates were recruited from the clinic. Most PD patients were recruited in the PD clinic; several were recruited during hospitalization. The Weill Cornell Institutional Review Board approved this protocol (IRB # 1604017181) and all participants provided written informed consent. Anterior nasal swab specimens were collected once from each participant using the Human Microbiome Project protocol. A Copan Eswab (Copan Diagnostics, Murietta, CA, USA) was inserted into the anterior part of one nostril of the participant and turned twice and was then inserted into the anterior part of the other nostril and turned twice. The Copan Eswab was then placed into 1 mL of liquid Amies provided by the Copan Eswab technology and immediately stored on ice or 4°C. Aliquots of 300 uL were created in 2 mL cryovial and stored at -80°C within 12 hours.

# 16S rRNA gene sequencing of the V4-V5 hypervariable region

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

A single aliquot of approximately 285 µL was deposited into a Oiagen PowerBead glass 0.1 mm tube. Using a Promega Maxwell RSC PureFood GMO and Authentication Kit (AS1600), 1mL of CTAB buffer & 20 µL of RNAse A Solution was added to the PowerBead tube containing the sample. The sample/buffer was mixed for 10 seconds on a Vortex Genie2 and then incubated at 95°C for 5 minutes on an Eppendorf ThermoMixer F2.0, shaking at 1500 rpm. The tube was removed and clipped to a horizontal microtube attachment on a Vortex Genie2 (SI-H524) and vortexed at high-speed for 20 minutes. The sample was removed from the Vortex and centrifuged on an Eppendorf Centrifuge 5430R at 40°C, 12700 rpm for 10 minutes. Upon completion, the sample was centrifuged again for an additional 10 minutes to eliminate foam. The tube was then added to a Promega MaxPrep Liquid Handler tube rack. The Liquid Handler instrument was loaded with proteinase K tubes, lysis buffer, elution buffer, 1000mL tips, 50mL tips, 96-sample deep-well plate, and Promega Maxwell RSC 48 plunger tips. The Promega MaxPrep Liquid Handler instrument was programed to use 300 µL of sample and transfer all sample lysate into Promega Maxwell RSC 48 extraction cartridge for DNA extraction. Upon completion, the extraction cartridge was loaded into Promega Maxwell RSC 48 for DNA extraction & elution. DNA was eluted in 100 µL and transferred to a standard 96-well plate. DNA was quantified using Quant-iT dsDNA High Sensitivity Assay Kit using Promega GloMax plate reader on a microplate (655087). 16S rRNA library generation followed the protocol from the Earth Microbiome Project.

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

Amplicon libraries were washed using Beckman Coulter AMPure XP magnetic beads. Library quality & size verification was performed using PerkinElmer LabChip GXII instrument with DNA 1K Reagent Kit (CLS760673). Library concentrations were quantified using Quant-iT dsDNA High Sensitivity Assay Kit using Promega GloMax plate reader on a microplate (655087). Library molarity was calculated based on library peak size & concentration. Libraries were normalized to 2nM using the PerkinElmer Zephyr G3 NGS Workstation (133750) and pooled together using the same volume across all normalized libraries into a 1.5mL Eppendorf DNA tube (022431021). Sequencing was performed on an Illumina MiSeq instrument at loading concentration of 7 pM with 15% PhiX, paired-end 250 using MiSeq Reagent Kit v2, 500-cycles (MS-102-2003). **Bioinformatics Pipeline** Demultiplexed raw reads were processed using the Nextflow (9) nf-core (10) amplised pipeline (11), version 2.2.0, with the following parameters: -profile singularity --input SampleSheet.tsv --FW primer GTGYCAGCMGCCGCGGTAA -- RV primer CCGYCAATTYMTTTRAGTTT -metadata Metadata.tsv --outdir results --dada ref taxonomy silva --ignore empty input files -ignore failed trimming --min frequency 10 --retain untrimmed --trunclenf 240 --trunclenr 160. Specifically, reads were trimmed with cutadapt (12), PhiX and quality filtering, read pair merging, and amplicon sequence variant resolution was performed with DADA2 (13). Subsequent taxonomic assignment was also performed with DADA2, using the Silva reference database (14), version 138. Sequences that were assigned the families, Chloroplast and Mitochondria, were removed from downstream analyses.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

**Biostatistical Analyses** The distribution of categorial variables were compared using Fisher's exact tests. The distribution of continuous variables were compared using Wilcoxon rank sum tests and to account for the comparison of multiple taxa, adjusted p values were calculated using Benjamini-Hochberg adjustment for multiple comparisons. DESeq2 was utilized to detect differences at the ASV between the groups using Benjamini-Hochberg adjustment. Comparison of correlations using a correlational matrix was adjusted for multiple comparisons using the Bonferonni method. All statistical tests were performed using R 4.1.3 in RStudio. Data Availability Sequencing data that support the findings of this study will be made available in the database of Genotypes and Phenotypes (dbGaP) phs002251.v1.p1 after peer-reviewed acceptance. Local institutional review board approval will be needed to access the data. **RESULTS** Characteristics of the Study Cohort and Nasal Microbial Sequencing The microbiota in the anterior nares was performing using 16S rRNA gene sequencing of the V4-V5 hypervariable region in 32 PD patients, 37 KTx recipients, 22 HC participants, and 3 negative controls. A total of 1,116,291 reads with assigned taxonomy was obtained in the cohort

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

of 91 participants with a median of 12,713 assigned reads with an interquartile range of 7,132 and 16,018 assigned reads. The number of assigned reads in the 3 negative controls were 146, 308, and 529, below the number in the cohort of participants. Table 1 shows the demographics of the participants. In general, the PD patients were older than the HC participants and similar in age to the KTx recipients. More than 50% of PD patients performed automated peritoneal dialysis and 15% had current Staphylococcus peritonitis or developed future Staphylococcus peritonitis within 10 to 12 months from the nasal specimen collection (last follow up). Approximately a third of KTx recipients received deceased donor transplantation and 32% were on trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis. Anterior Nasal Microbial Diversity Differs Across the Study Cohort Microbial diversity among the study participants was measured at the ASV level using the Shannon diversity, an index that evaluates the richness and evenness in a community, as well as Chao1, an index that estimates the total number of ASVs in the specimens. Fig. 1A and B show box and whisker plots of these diversity indices and reveal that PD patients had a significantly higher Shannon diversity index and Chao1 diversity index than KTx recipients (P<0.05, Wilcoxon rank sum test) but similar to the HC participants (P>0.05). Staphylococcus Abundance Negatively Correlates with Corynebacterium Abundance in **Anterior Nasal Specimens** 

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

We further evaluated the anterior nasal microbiota among the study cohort at the genus level. At the genus level, the top abundant genera (>1% mean abundance across the cohort) included Staphylococcus, Corynebacterium, Anaerococcus, Streptococcus, unspecified Neisseriaceae, Moraxella, Cutibacterium, Peptoniphilus, and Finegoldia (Fig. 2A). We performed a correlational matrix analysis among each of the genera (Fig. 2B). The relative abundance of Staphylococcus was inversely correlated with that of Corynebacterium (Pearson r = -0.66, adjusted P value < 0.10, Benjamini-Hochberg adjustment). The relative abundances of Peptoniphilus was positively associated with that of Anaerococcus (r=0.52, adjusted P value < 0.10) and of Finegoldia (r=0.27, adjusted P value < 0.10). The relative abundance of Finegoldia was positively associated with that of *Anaerococcus* (r= 0.60, adjusted P value < 0.10). The relative abundance of Unspecified *Neisseriaceae* was positively associated with that of Cutibacterium (r= 0.31, adjusted P value < 0.10). Distinct Anterior Nasal Microbiota Define PD Patients and Kidney Transplant Recipients The individual profiles of the top genera in anterior nasal microbiota are shown in the PD patients, KTx recipients, and HC participants (Fig. 3). Fig. 4 shows box and whisker plots of the top 9 taxa among the PD patients, the KTx recipients, and the HC participants and Table 2 shows the comparisons among the groups using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment. PD patients had a distinctly higher relative abundance of *Streptococcus* than KTx recipients or HC participants (Adjusted P value < 0.10, Wilcoxon rank sum test, Benjamini-Hochberg adjustment) (Fig. 4D). PD patients also had lower abundance of unspecified Neisseriaceae, Moraxella, Cutibacterium, and Peptoniphilus than HC participants (Fig. 4G)

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

(Adjusted P value < 0.10). Kidney transplant recipients had a lower abundance of *Moraxella* than HC participants (Adjusted P value < 0.10). Other than Streptococcus, KTx recipients had similar abundance of the top genera compared to PD patients (Adjusted P value > 0.10). In order to gain further insight, we evaluated the taxa at the ASV level. We performed pairwise DESeq2 between the groups to identify ASVs that were consistently different among the groups. Fig. 5 shows the significant log2 fold abundance changes between the groups and SI Tables 1 to 3 reveal the changes in the nasal abundances of the groups. Both PD patients and KTx recipients had significantly higher nasal abundances of Staphylococcus ASV #1 and Corynebacterium ASV #1 and lower abundance of Anaerococcus ASV #1 than HC participants (Adjusted p value < 0.10, Benjamini-Hochberg adjustment). PD patients had higher nasal abundance of Staphylococcus ASV #2, Abiotrophia ASV #1, and Porphyromonas ASV #1 than KTx recipients or HC participants (Adjusted p value < 0.10). PD Patients Have a More Diverse Representation of Staphylococcus and Streptococcus than KTx Recipients and HC Participants To further understand why PD patients have higher microbial diversity, we evaluated the diversity of ASVs in the most common genera: Staphylococcus, Corynebacterium, and Streptococcus. There were 61 different Staphylococcus ASVs identified in the whole cohort. PD patients had a significantly higher number of Staphylococcus ASVs per specimen than KTx patients (P=0.03, Wilcoxon rank sum test) and HC participants (P=0.04). There were 95 different Corynebacterium ASVs identified in the whole cohort. PD patients, KTx patients, and HC

participants had similar number of *Corynebacterium* ASVs per specimen (P>0.10). There were 46 different *Streptococcus* ASVs identified in the whole cohort. PD patients had a significantly higher number of *Streptococcus* ASVs per specimen than KTx patients (P=0.04) and HC participants (P=0.05).

### Clinical Factors, Outcomes, and the Nasal Microbiota

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

We next evaluated the relationship among the nasal microbiota, clinical factors, and outcomes in the cohort. There were no significant differences in the nasal abundances of the most common genera based upon age greater than or equal to 65 years old (SI Table 4). The relative abundance of *Peptoniphilus* was significantly higher in male patients than in female patients (adjusted P value < 0.10) (SI Table 5). Twelve of the kidney transplant recipients were on TMP-SMX prophylaxis for *Pneumocystic jirovecii* prophylaxis and 35 were not. There were no significant differences in the nasal abundance of the most common genera between the kidney transplant recipients on TMP-SMX and those who were not (SI Table 6). In the PD cohort, 6 PD patients concurrently had Staphylococcus peritonitis or developed future Staphylococcus peritonitis within 10 to 12 months (last follow up) (Staph Peritonitis Group) and 26 PD patients did not (No Staph Peritonitis Group). The nasal abundance of *Staphylococcus* was higher in the Staph Peritonitis Group than in the No Staph Peritonitis Group but the difference was not statistically significant (median abundance 52% vs. 24%, respectively, adjusted P value 0.73). There were no significant differences in the nasal abundance of the other most common genera between the Staph Peritonitis Group and the No Staph Peritonitis Group (SI Table 7).

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

**DISCUSSION** This study aimed to describe the anterior nasal microbiota across different groups of patients with kidney disease. We detect a distinct microbial signature in the anterior nares of PD patients compared to KTx recipients and HC participants. Many of the most common genera in the kidney cohort overlap with those reported in healthy individuals and include Staphylococcus, Corynebacterium, Finegoldia, and Cutibacterium (15, 16). However, there were some distinct differences among the groups. PD patients had a higher nasal abundance of Streptococcus than HC participants or KTx recipients. Interestingly, having a higher nasal abundance of Streptococcus has been associated with respiratory infections such as bronchiolitis in infants (17). While the most common type of infectious peritonitis is Staphylococcus in origin, Streptococcus peritonitis also occurs in PD patients. Our study was not able to directly address whether PD patients with nasal abundance of Streptococcus is associated with Streptococcus peritonitis and/or respiratory viral infections, but such a link would provide the groundwork for novel approaches to manipulate the nasal microbiota to prevent such complications. In our analysis, we noticed a higher nasal microbial diversity in the PD patients compared to KTx recipients and HC participants. Further analysis showed that part of this increased microbial diversity may be due to a more diverse representation of Staphylococcus and Streptococcus in PD patients (Fig. 6). This may have interesting implications as prior data suggests that PD patients with Staphylococcus aureus colonization had a higher incidence of exit site infections

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

(Ref). In our study, we did find an increased nasal abundance of *Staphylococcus* in PD patients who had a history of *Staphylococcus* peritonitis and/or developed *Staphylococcus* peritonitis. While the association was not significant, it could be due to the low number of PD patients in the PD Staph peritonitis as our study was not powered to detect the differences. At the 16S rRNA level, we were not able to determine Staphylococcus at the species level and this limitation prevented us to assess this association in more detail. Our data also highlight a strong inverse association between the nasal abundance of Staphylococcus and that of Corynebacterium. Interesting mechanistic studies have shown a complicated relationship between these two taxa, which represent the most common taxa in the nasal microbiota. One study found that Corynebacterium species can secrete antimicrobial peptides against Staphylococcus aureus (18). Another study has shown that Corynebacterium species can decrease the virulence of S. aureus (19). Taken together, our data are consistent with the inverse relationship and suggest potential novel approaches to manipulate the nasal microbiota. For example, since Staphylococcus peritonitis is much more common than Corynebacterium peritonitis, establishing a Corynebacterium dominant nasal microbiota may be preventative of Staphylococcus in the nasal passages and possibly decrease the risk for Staphylococcus exit site infection and/or peritonitis. A surprising result is that we did not find an association between the TMP/SMX and nasal microbiota differences. TMP/SMX has broad coverage against gram positive cocci including Staphylococcus species. There are few studies which have investigated the role of oral antibiotics on the nasal microbiota and it is possible that intra-nasal antibiotics rather than oral antibiotics

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

may more efficiently impact the nasal microbiota. While our study is limited by the population size and the cross-sectional nature, our study raises this possibility. There are several limitations to our study. As mentioned prior, we are unable to assess species level identification via 16S rRNA gene sequencing of the V4-V5 hypervariable region. Future studies using whole gene 16S rRNA gene sequencing or metagenomic sequencing may provide better resolution on the intricate intra-species competition between the microbiota, particularly between Staphylococcus species, and Corynebacterium species. Given the low biomass of the nasal microbiota, environmental contamination and/or contamination through the DNA processing steps could artificially introduce microbiota in our specimens. However, we did sequence negative controls (Fig. 3) and the most abundant microbiota identified were not the most common nasal microbiota flora previously reported, suggesting that the nasal microbiota identified in our cohort was present in higher quantities and distinct. The cross-sectional nature of our study provides a snapshot of the microbiota across different groups of patients with kidney disease but does not provide longitudinal changes. Such a longitudinal study may provide more insight into the relationship between the microbiota and clinical factors and outcomes in the populations. In conclusion, we provide the first description of a distinct nasal microbiota signature in PD patients compared to KTx recipients and HC participants. We find a higher abundance of Streptococcus and a more diverse representation of Staphylococcus and Streptococcus in PD patients. Given the potential relationship between the nasal bacteria and infectious complications in PD patients, further studies are needed to define the nasal microbiota associated with these

- 362 infectious complications and to conduct studies on the manipulation of the nasal microbiota to
- 363 prevent such complications.

18

365 REFERENCES 366 367 1. Human Microbiome Project C. Structure, function and diversity of the healthy human 368 microbiome. Nature. 2012;486(7402):207-14. 369 2. Chen F, Gao W, Yu C, Li J, Yu F, Xia M, et al. Age-Associated Changes of Nasal Bacterial 370 Microbiome in Patients With Chronic Rhinosinusitis. Front Cell Infect Microbiol. 371 2022;12:786481. 372 3. Hsiao CJ, Paulson JN, Singh S, Mongodin EF, Carroll KC, Fraser CM, et al. Nasal 373 Microbiota and Infectious Complications After Elective Surgical Procedures. JAMA Netw 374 Open. 2021;4(4):e218386. 375 4. Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, et al. Staphylococcus 376 aureus nasal carriage and infection in patients on continuous ambulatory peritoneal 377 dialysis. N Engl J Med. 1990;322(8):505-9. 378 5. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, and van Belkum A. Persistent (not 379 intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related 380 infections. Kidney Int. 2005;67(3):1084-92. 381 6. Ong LM, Ch'ng CC, Wee HC, Supramaniam P, Zainal H, Goh BL, et al. Risk of Peritoneal 382 Dialysis-Related Peritonitis in a Multi-Racial Asian Population. Perit Dial Int. 383 2017;37(1):35-43. 384 7. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal 385 dialysis. Mupirocin Study Group. J Am Soc Nephrol. 1996;7(11):2403-8.

386	8.	Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD Peritonitis
387		Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int.
388		2016;36(5):481-508.
389	9.	Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, and Notredame C. Nextflow
390		enables reproducible computational workflows. Nat Biotechnol. 2017;35(4):316-9.
391	10.	Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework
392		for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276-8.
393	11.	Straub D, Blackwell N, Langarica-Fuentes A, Peltzer A, Nahnsen S, and Kleindienst S.
394		Interpretations of Environmental Microbial Community Studies Are Biased by the
395		Selected 16S rRNA (Gene) Amplicon Sequencing Pipeline. Front Microbiol.
396		2020;11:550420.
397	12.	Martin M. Cutadapt removes adapter sequences from high-throughput sequencing
398		reads. EMBnetjournal. 2011;17: https://doi.org/10.14806/ej.17.1.200.
399	13.	Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, and Holmes SP. DADA2: High-
400		resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581-
401		3.
402	14.	Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal
403		RNA gene database project: improved data processing and web-based tools. <i>Nucleic</i>
404		Acids Res. 2013;41(Database issue):D590-6.
405	15.	Oh J, Conlan S, Polley EC, Segre JA, and Kong HH. Shifts in human skin and nares
406		microbiota of healthy children and adults. Genome Med. 2012;4(10):77.

407 Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, and Scheperjans F. Oral and 16. 408 nasal microbiota in Parkinson's disease. Parkinsonism Relat Disord. 2017;38:61-7. 409 17. Hasegawa K, Linnemann RW, Mansbach JM, Ajami NJ, Espinola JA, Petrosino JF, et al. 410 Nasal Airway Microbiota Profile and Severe Bronchiolitis in Infants: A Case-control 411 Study. Pediatr Infect Dis J. 2017;36(11):1044-51. 412 18. Menberu MA, Liu S, Cooksley C, Hayes AJ, Psaltis AJ, Wormald PJ, et al. Corynebacterium accolens Has Antimicrobial Activity against Staphylococcus aureus and Methicillin-413 414 Resistant S. aureus Pathogens Isolated from the Sinonasal Niche of Chronic 415 Rhinosinusitis Patients. Pathogens. 2021;10(2). 416 19. Ramsey MM, Freire MO, Gabrilska RA, Rumbaugh KP, and Lemon KP. Staphylococcus 417 aureus Shifts toward Commensalism in Response to Corynebacterium Species. Front 418 Microbiol. 2016;7:1230. 419 420

421 TABLE 1

	PD Cohort (n=32)	KTx Cohort (n = 37)	HC Cohort $(n = 22)$
Characteristic	median abundance	median abundance	median abundance
Age, years	63 (51, 73)	59 (52, 67)	51 (33, 61)
Female Sex	20 (63%)	17 (46%)	13 (59%)
Ethnicity			
Hispanic	3 (9%)	2 (5%)	3 (14%)
Non-Hispanic	27 (84%)	33 (89%)	16 (73%)
Declined	2 (6%)	2 (5%)	3 (14%)
Race			
Asian	4 (11%)	4 (11%)	1 (5%)
Black	13 (41%)	10 (27%)	5 (23%)
White	11 (34%)	20 (54%)	11 (50%)
Other	3 (9%)	2 (5%)	1 (5%)
Declined	1 (3%)	1 (3%)	4 (18%)
History of Hypertension	26 (81%)	36 (97%)	2 (9%)
History of Diabetes Mellitus	9 (28%)	12 (32%)	0 (0%)
Years on PD	1.2 (0.6, 2.4)		
Automated Peritoneal Dialysis	21 (66%)		
Concurrent or Develops Future			
Staphylococcus Peritonitis	6 (19%)		
Decreased Donor Transplantation		14 (38%)	
Days Post Transplantation		364 (51, 1637)	
History of Prior Transplantation		4 (11%)	
Maintenance Immunosuppression			
Tacro/mycophenolic mofetil		19 (51%)	
Tacro/mycophenolic mofetil/pred		14 (38%)	
Tacro/mycophenolic acid		1 (3%)	
Tacro/mycophenolic acid/pred		3 (8%)	
Trimethoprim/Sulfamethoxazole PPx 22		12 (32%)	

<sup>423</sup> Demographics of the Cohort. Categorical variables are represented by the number followed by the 424


percentage in parentheses. Continuous variables are represented by the median followed by the

<sup>425</sup> interquartile range in parentheses.


TABLE 2

	PD Cohort (n=32) median	KTx Cohort $(n = 37)$ median	HC Cohort (n = 22) median	PD vs. HC	PD vs. HC	PD vs. KTx	PD vs. KTx	KTx vs. HC	KTx vs. HC
Genus	abundance	abundance	abundance	P value	Adj P Value	P value	Adj P Value	P value	Adj P Value
Anaerococcus	0.020	0.004	0.014	0.999	0.999	0.238	0.722	0.303	0.389
Corynebacterium	0.098	0.200	0.127	0.509	0.573	0.271	0.722	0.701	0.701
Cutibacterium	0.000	0.000	0.009	0.016	0.049	0.942	0.942	0.029	0.133
Finegoldia	0.000	0.000	0.001	0.098	0.147	0.660	0.880	0.178	0.320
<i>Moraxella</i> Unspecified	0.000	0.000	0.000	0.014	0.049	NA	NA	0.008	0.074
Neisseriaceae	0.000	0.000	0.003	0.034	0.062	0.510	0.817	0.105	0.237
Peptoniphilus	0.000	0.000	0.013	0.022	0.049	0.382	0.763	0.046	0.139
Staphylococcus	0.249	0.403	0.257	0.406	0.522	0.891	0.942	0.285	0.389
Streptococcus	0.027	0.005	0.003	0.001	0.008	0.003	0.027	0.584	0.657

Comparison of the Nasal Abundance Among the 3 Cohorts at the Genus Level. The median abundance of the most common genera are shown for the peritoneal dialysis (PD) cohort, the kidney transplant cohort (KTx), and the living donor /healthy control (HC) cohort. P values shown were calculated using Wilcoxon rank sum test between groups. Adjusted P value (Adj P Value) were calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups.




Distinct Differences in Nasal Microbial Diversity among the Study Cohort. Panel A shows box and whisker plots of Chao1 index, the estimated number of amplicon sequence variants, in the anterior nasal specimens from the peritoneal dialysis (PD) cohort, the kidney transplant cohort (Ktx), and the living donor /healthy control (HC) cohort. The Chao1 index is on the y axis and the study group is on the x-axis. P value shown was calculated by Wilcoxon rank sum test. Panel B shows box and whisker plots of Shannon diversity index, a measure of evenness and richness, in the anterior nasal specimens from the 3 cohorts. The Shannon diversity index is on the y axis and the study group is on the x-axis. P values shown were calculated by Wilcoxon rank sum test.




Significant Correlations among the Most Common Genera in the Study Cohort. Panel A shows the most common genera in the anterior nasal microbiota (>1% mean relative abundance in the cohort). Box and whisker plots are represented to show the variation in the relative abundance of the genus (y-axis) with the genus on the x-axis. Panel B shows a correlational


matrix between the nasal abundance of the most common genera using Pearson's r correlations with Benjamini-Hochberg adjustment for multiple hypotheses. The numbers shown are Pearson's r correlations that had an adjusted P value < 0.10. The color shows the strength of the correlation with red showing a positive correlation between two genera and blue showing a negative correlation between two genera.




Individual Microbiota Profiles by the Study Cohort. The relative abundance of microbiota is on the y axis and individual nasal specimens are on the x-axis. The relative abundance of each genus is represented by color. The top panel represents anterior nasal microbiota profiles from the 32 peritoneal dialysis (PD) patients, the middle panel represents the anterior nasal microbiota profiles from the 37 kidney transplant (KTx) patients, and the bottom panel represents the anterior nasal microbiota profiles from the 22 potential living donor / healthy control (HC) participants. The right panel represents the microbiota from 3 negative controls.



**Distinct microbial differences among the cohort at the genus level.** Box and whisker plots are represented with the relative abundance of individual genera on the y axis and the group on the x axis. PD, peritoneal dialysis cohort (n=32). KTx, kidney transplant cohort (n=37). HC, living donor / healthy control cohort (n=22). P values were calculated using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment for multiple hypothesis. \*\* Adjusted P value < 0.05 \* Adjusted P value < 0.10. **Panel A**, *Staphylococcus* analysis. **Panel B**, *Corynebacterium* analysis. **Panel C**, *Anaerococcus* analysis. **Panel D**, *Streptococcus* analysis. **Panel E**, Unspecified *Neisseriaceae* analysis. **Panel F**, *Moraxella* analysis. **Panel G**, *Cutibacterium* analysis. **Panel H**, *Peptoniphilus* analysis. **Panel I**. *Finegoldia* analysis.



Differential abundance analyses among the cohort at the amplicon sequence variant level. Differential abundance analyses were performed on the anterior nasal microbiota between the groups using DESeq2 with Benjamini-Hochberg adjustment for multiple hypothesis testing. On the y axis is the individual amplicon sequence variant with genus shown and on the x axis is the fold difference in abundance. PD, peritoneal dialysis cohort. KTx, kidney transplant cohort. HC, living donor / healthy control cohort. The fold difference directionality is represented above the graph. Panel A represents differential abundance analyses between the HC Group and the PD Group. Panel B represents differential abundance analyses between the KTx Group and the KTx Group.



**Diverse representation of the most common genera in the study cohort.** Each set of graphs represents the number of amplicon sequence variant (ASV) from a particular genus by group. PD, peritoneal dialysis group (n=32). KTx, kidney transplant group (n=37). HC, living donor / healthy control group (n=22). The top graph presents box and whisker plots of the number of ASVs per specimen by group. P value was calculated using Wilcoxon rank sum test: \*\* P value < 0.05 \* P value < 0.10. The bottom 3 graphs represent box and whisker plots of the relative abundance of individual ASVs from a particular genus. The relative abundance is on the y axis with the color representing individual ASVs and anterior nasal specimens are on the x axis with the second top graph representing the PD Cohort, the second bottom graph representing the KTx Cohort, and the bottom graph representing the HC Cohort. **Panel A** shows the diversity of *Staphylococcus* ASVs in the study cohort. **Panel B** shows the diversity of *Corynebacterium* ASVs in the study cohort. **Panel C** shows the diversity of *Streptococcus* ASVs in the study cohort.

SI Table 1

Genus	ASV	Base Mean	log2 Fold Change	Standard error	Wald stat	P value	Adj P value
Finegoldia ASV #1	1f016ec26e4774c86f029301b556de28	24.3	-26.4	2.9	-9.0	3.4E-19	1.4E-17
Anaerococcus ASV #1	ae7cf0f32080cf5e62b3fbd903a997af	16.5	-25.9	3.0	-8.7	2.2E-18	4.4E-17
Lawsonella ASV #1	b89dbfe5c74375ff3d4922b41c470740	49.0	-7.3	2.9	-2.5	1.3E-02	5.1E-02
Corynebacterium ASV #2	c91b64f1467982a81922d331a310f5dc	1172.2	-3.7	1.6	-2.2	2.5E-02	9.2E-02
Bacillus ASV #1	5565e52f91bc244013249656795409ca	18.7	6.9	1.8	3.8	1.7E-04	7.7E-04
Staphylococcus ASV #2	b273d7d05f0525bb87418b0138d90605	86.0	11.8	2.2	5.3	1.2E-07	6.1E-07
$Porphyromonas\ ASV\ \#I$	969732ae717bf5a9282f4781499aadb4	10.0	21.4	3.0	7.2	6.3E-13	3.6E-12
Abiotrophia ASV #1	afce1dc2c06acb90ad5d3da0fffbcd02	9.7	22.3	2.8	7.9	3.5E-15	2.4E-14
Streptococcus ASV #1	4481bc66d3a54f79e6abb8b557a2a104	19.3	23.2	2.9	7.9	2.5E-15	2.4E-14
Staphylococcus ASV #1	7b06c22a4ff85c9b2cbbf57a53462e13	41.9	23.4	3.0	7.9	3.6E-15	2.4E-14
Corynebacterium ASV #1	0560198302010f9b110d4ec9897e14d0	45.9	24.5	3.0	8.2	1.8E-16	2.3E-15

**DESeq2 Analysis of the Nasal Microbiota between the PD Group and the HC Group.** The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald statistic. Positive log2 Fold Change is higher in the PD Group.

SI Table 2

			log2 Fold				
Genus	ASV	Base Mean	Change	Standard error	Wald stat	P value	Adj P value
Staphylococcus ASV #3	0f89ba63b47f3b624c13293cb4d56486	16.5	-25.6	2.9	-8.8	1.9E-18	2.0E-16
Porphyromonas ASV #1	969732ae717bf5a9282f4781499aadb4	7.4	21.6	2.9	7.4	1.1E-13	4.8E-12
Abiotrophia ASV #1	afce1dc2c06acb90ad5d3da0fffbcd02	7.3	23.3	2.8	8.4	4.3E-17	3.0E-15
Corynebacterium ASV #3	36f00e24a741c19a5ee20f58919004ad	12.4	24.0	2.9	8.2	1.7E-16	8.8E-15
Staphylococcus ASV #2	b273d7d05f0525bb87418b0138d90605	65.8	24.8	2.4	10.2	1.5E-24	3.1E-22

**DESeq2 Analysis of the Nasal Microbiota between the PD Group and the KTx Group.** The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald stat, Wald statistic. Positive log2 Fold Change is higher in the PD Group.

SI Table 3

Genus	ASV	Base Mean	log2 Fold Change	Standard error	Wald stat	P value	Adj P value
Anaerococcus ASV #1	ae7cf0f32080cf5e62b3fbd903a997af	12.0	-25.4	3.0	-8.5	2.8E-17	2.2E-15
Corynebacterium ASV #4	9f6c00ff9e1f455f42f211770d60dec0	11.2	-25.3	3.0	-8.4	3.6E-17	2.2E-15
Staphylococcus ASV #3	0f89ba63b47f3b624c13293cb4d56486	12.5	21.6	3.0	7.2	7.4E-13	2.8E-11
Staphylococcus ASV #1	7b06c22a4ff85c9b2cbbf57a53462e13	11.8	22.9	3.0	7.6	2.8E-14	1.3E-12
Corynebacterium ASV #1	0560198302010f9b110d4ec9897e14d0	237.4	27.1	3.0	9.0	2.2E-19	4.1E-17

**DESeq2 Analysis of the Nasal Microbiota between the KTx Group and the HC Group.** The listed ASV were determined to be significantly different using an adjusted p value of 0.10. Base Mean, mean of normalized counts for all samples. Wald statistic. Positive log2 Fold Change is higher in the KTx Group.

SI Table 4

	Age >= 65 $n = 28$	Age < 65 $n = 63$		
Genus	Median Abundance	Median Abundance	P value	Adj P value
Staphylococcus	0.187	0.346	0.11	0.40
Finegoldia	0.000	0.001	0.11	0.40
Anaerococcus	0.001	0.013	0.14	0.40
Moraxella	0.000	0.000	0.18	0.40
Unspecified Neisseriaceae	0.000	0.000	0.30	0.48
Streptococcus	0.012	0.007	0.32	0.48
Corynebacterium	0.124	0.139	0.56	0.72
Peptoniphilus	0.000	0.000	0.66	0.74
Cutibacterium	0.003	0.002	0.81	0.81

Comparison of Nasal Microbiota Based on Patient's Age at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment.

SI Table 5

	Female Sex	Male Sex		
	n = 50	n = 41		
Genus	Median Abundance	Median Abundance	P value	Adj P value
Peptoniphilus	0.000	0.005	0.01	0.10
Finegoldia	0.000	0.002	0.07	0.31
Anaerococcus	0.002	0.017	0.19	0.51
Corynebacterium	0.101	0.197	0.23	0.51
Cutibacterium	0.002	0.007	0.38	0.64
Moraxella	0.000	0.000	0.43	0.64
Unspecified Neisseriaceae	0.000	0.000	0.90	0.91
Streptococcus	0.008	0.010	0.90	0.91
Staphylococcus	0.285	0.250	0.91	0.91

Comparison of Nasal Microbiota Based on Patient's Sex at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment.

SI Table 6

	KTx on TMP/SMX	KTx off TMP/SMX		
	n = 12	n = 25		
Genus	Median Abundance	Median Abundance	P value	Adj P value
Finegoldia	0.000	0.002	0.02	0.15
Peptoniphilus	0.000	0.000	0.04	0.15
Anaerococcus	0.0002	0.007	0.06	0.15
Corynebacterium	0.101	0.314	0.36	0.59
Cutibacterium	0.000	0.000	0.37	0.59
Staphylococcus	0.363	0.487	0.53	0.71
Unspecified Neisseriaceae	0.000	0.000	0.70	0.80
Streptococcus	0.002	0.005	0.84	0.84
Moraxella	0.000	0.000	NA	NA

Comparison of Nasal Microbiota Based on Trimethoprim/Sulfamethoxazole usage in the Kidney Transplant Recipients at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups. KTx, Kidney Transplant; TMP/SMX, trimethoprim/sulfamethoxazole.

## SI Table 7

	PD Staph	PD No Staph		
	Future	Future		
	Peritonitis	Peritonitis		
	n = 6	n = 26		
Genus	Median Abundance	Median Abundance	P value	Adj P value
Unspecified Neisseriaceae	0.000	0.000	0.08	0.66
Staphylococcus	0.521	0.240	0.38	0.73
Streptococcus	0.009	0.035	0.38	0.73
Anaerococcus	0.0002	0.022	0.39	0.73
Peptoniphilus	0.000	0.000	0.48	0.73
Cutibacterium	0.001	0.000	0.55	0.73
Finegoldia	0.000	0.000	0.76	0.87
Corynebacterium	0.101	0.098	1.00	1.00
Moraxella	0.000	0.000	NA	NA

Comparison of Nasal Microbiota Based on PD patients who developed *Staphylococcus* peritonitis status and PD patients who did not develop *Staphylococcus* peritonitis at the Genus Level. P value was calculated between groups using Wilcoxon rank sum test. Adjusted p value (Adj P value) was calculated using Benjamini-Hochberg adjustment. P values with NA were unable to be calculated because the abundances were 0 in both groups. PD Staph peritonitis cohort was defined as PD patients who currently had *Staphylococcus* peritonitis or developed *Staphylococcus* peritonitis withn 10 to 12 months (last follow up).